Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

More about accessibility

Trouble using our website?
Contact us

Text logo ERN-EYE Tools
CPMS REDgistry Elearning Members area
Accessibility

THOR

In this page

Clinical Trial

NCT02671539 Completed
THOR

Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using anadeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)

Phase 2
Interventional

Disease

Disease type

Choroideremia

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

11/01/2016

Closing date

09/02/2016

Inclusion criteria :

More

Exclusion criteria :

More

Funding

other

Members involved

Main investigators

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

Substitute

Germany

See more

ERN EYE member investigating site

HCP : Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

Adress

Department für Augenheilkunde Tübingen Forschungsinstitut für Augenheilkunde Elfriede-Aulhorn-Str. 7

72076 Tübingen

Germany

Contact

07071 29-84021

Website

See full page
More